HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease.

Abstract
The aim of this study was to evaluate the safety and the biological effects of interleukin (IL-1 alpha) in patients' with recurrent ovarian carcinoma treated with carboplatin. In this phase I study, IL-1 alpha was administered by a continuous intravenous infusion at doses ranging 0.1-10 micrograms/m2 every 24 h for 4 days (96 h) 3 weeks before the first dose of carboplatin (400 mg/m2) in patients with potentially platinum-sensitive ovarian cancer. The maximum tolerated dose was 3 microgram/m2/day. Dose-limiting effects at 10 micrograms/m2/day were fever, chills, hypotension and fluid retention. Minor but objective antitumour effects were observed in 2 of 18 patients. 4 patients (including 1 with a minor response) had a decrease of the CA-125 serum level ranging from 33 to 39%. The trial design precluded evaluation of the duration of response to single-agent IL-1 alpha. Based on this trial design, there is evidence of minor antitumour effect to a single course of IL-1 alpha dose given prior to chemotherapy.
AuthorsC F Verschraegen, A P Kudelka, W Termrungruanglert, C G de Leon, C L Edwards, R S Freedman, J J Kavanagh, S Vadhan-Raj
JournalEuropean journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 32A Issue 9 Pg. 1609-11 (Aug 1996) ISSN: 0959-8049 [Print] England
PMID8911126 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CA-125 Antigen
  • Interleukin-1
Topics
  • Adult
  • Aged
  • CA-125 Antigen (blood)
  • Female
  • Humans
  • Interleukin-1 (adverse effects, therapeutic use)
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: